DNMT3A and acute myeloid leukemia: It remains also to be determined if DNMT3A mutations affect in a similar way the metabolism of other compounds that intercalates DNA and inhibits topoisomerase II such as the new quinolone derivative vosaroxin which is currently assessed in AML [31].